ICMR has developed the indigenous Covid-19 vaccine (BBV152 COVID Vaccine) with BBIL. ICMR has selected 12 institutes for clinical trials of the country’s first indigenous Covid-19 vaccine. In a letter to these institutions, ICMR stated that it is envisaged to launch the vaccine for public health use by August 15, 2020, after the completion of all clinical trials. ICMR has partnered with Bharat Biotech for clinical trials of indigenous Corona Vaccine
The whole world is waiting for the vaccine to win the war against the Coronavirus. India has achieved great success in vaccine development like a few selected countries in the world. Hyderabad-based biotechnology company Bharat Biotech is going to start human trials of its corona vaccine in July. The company on Monday claimed to have successfully produced the country’s first Covid-19 vaccine Covaxin. The company has also said that it has received human trial approval from the Drug Controller General of India (DGCI).
The statement issued by the company said that the vaccine has been prepared in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV).
“The SARS-COV-2 strain is isolated at NIV Pune and then sent to Bharat Biotech,” the company said. The indigenous inactivated vaccine was developed and then produced at Bharat Biotech’s BSL-3 (Bio-Safety Level 3) High Containment Facility. It is located in Genome Valley, Hyderabad.
After finding a safe and immune response in pre-clinical studies, the result was submitted to the Drug Controller under the Union Ministry of Health. The drug controller then approved human clinical trials for phase I and phases II.
Dr. Krishna Illa, Chairman and Managing Director of Bharat Biotech said, “Human trials will be started across the country in July 2020.” He said that vaccine development is a milestone and the company is proud to announce it.
Bharat Biotech’s research and epidemic prediction ability led to the development of a vaccine for the H1N1 pandemic.